Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,411.20
(
-2.35%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,198.48
(
-0.21%
)
News Focus
News Focus
Post# of 257300
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rstor1 post# 1122

Saturday, 02/07/2004 9:52:48 PM

Saturday, February 07, 2004 9:52:48 PM

Post# of 257300
>> Are you expecting them to run the PIII as the dosing trial? Pharma doesn't like to do that. They like their ducks all in a row by the time they get to the pivotal trials. <<

Eyetech tested three doses in each of their phase-3 Macugen trials, so it can be done.

Squalamine’s dose for AMD is pretty well set at 25mg/m2. What is still malleable is the dosing interval to be used following the initial loading regimen of four weekly infusions.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today